BiotechTube

Clazosentan 5 m/h + Clazosentan 15 mg/h + Placebo

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Aneurysmal Subarachnoid Hemorrhage

Conditions

Aneurysmal Subarachnoid Hemorrhage

Trial Timeline

Jul 1, 2009 → Jan 1, 2011

NCT ID
NCT00940095

About Clazosentan 5 m/h + Clazosentan 15 mg/h + Placebo

Clazosentan 5 m/h + Clazosentan 15 mg/h + Placebo is a phase 3 stage product being developed by Idorsia for Aneurysmal Subarachnoid Hemorrhage. The current trial status is terminated. This product is registered under clinical trial identifier NCT00940095. Target conditions include Aneurysmal Subarachnoid Hemorrhage.

What happened to similar drugs?

0 of 3 similar drugs in Aneurysmal Subarachnoid Hemorrhage were approved

Approved (0) Terminated (0) Active (3)
🔄Clazosentan + PlaceboIdorsiaPhase 3
🔄Clazosentan + PlaceboIdorsiaPhase 3
🔄GTX-104 + Nimotop 30 MG Oral CapsuleGrace TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00940095Phase 3Terminated

Competing Products

8 competing products in Aneurysmal Subarachnoid Hemorrhage

See all competitors
ProductCompanyStageHype Score
erythropoietin betaRochePhase 2
35
DenosumabAmgenPhase 2
31
Clazosentan + PlaceboIdorsiaPhase 3
34
ClazosentanIdorsiaPhase 2
29
Clazosentan + PlaceboIdorsiaPhase 3
34
Clazosentan 1 mg/h + Clazosentan 5 mg/h + Clazosentan 15 mg/h + PlaceboIdorsiaPhase 2
29
GTX-104 + Nimodipine CapsulesGrace TherapeuticsPhase 1
19
GTX-104 + Nimotop 30 MG Oral CapsuleGrace TherapeuticsPhase 3
34